Bioconjugation of Podophyllotoxin and Nanosystems: Approaches for Boosting Its Biopharmaceutical and Antitumoral Profile

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2025 Feb 26

PMID 40005983

Authors

Carolina Miranda-Vera

Angela-Patricia Hernandez

Pilar Garcia-Garcia

David Diez

Pablo A Garcia

Maria Angeles Castro

Affiliations

Soon will be listed here.

Abstract

Podophyllotoxin is a natural compound belonging to the lignan family and is well-known for its great antitumor activity. However, it shows several limitations, such as severe side effects and some pharmacokinetics problems, including low water solubility, which hinders its application as an anticancer agent. Over the past few years, antitumor research has been focused on developing nanotechnology-based medicines or nanomedicines which allow researchers to improve the pharmacokinetic properties of anticancer compounds. Following this trend, podophyllotoxin nanoconjugates have been obtained to overcome its biopharmaceutical drawbacks and to enhance its antitumor properties. The objective of this review is to highlight the advances made over the past few years (2017-2023) regarding the inclusion of podophyllotoxin in different nanosystems. Among the huge variety of nanoconjugates of diverse nature, drug delivery systems bearing podophyllotoxin as cytotoxic payload are organic nanoparticles mainly based on polymer carriers, micelles, and liposomes. Along with the description of their pharmacological properties as antitumorals and the advantages compared to the free drug in terms of biocompatibility, solubility, and selectivity, we also provide insight into the synthetic procedures developed to obtain those podophyllotoxin-nanocarriers. Typical procedures in this regard are self-assembly techniques, nanoprecipitations, or ionic gelation methods among others. This comprehensive perspective aims to enlighten the medicinal chemistry community about the tendencies followed in the design of new podophyllotoxin-based drug delivery systems, their features and applications.

References

Xiang C, Fu Y, Hao T, Wei L, Liu Y, Fan Z . Podophyllotoxin-loaded PEGylated E-selectin peptide conjugate targeted cancer site to enhance tumor inhibition and reduce side effect. Eur J Med Chem. 2023; 260:115780. DOI: 10.1016/j.ejmech.2023.115780. View

Li C, Wang Y, Zhang S, Zhang J, Wang F, Sun Y . pH and ROS sequentially responsive podophyllotoxin prodrug micelles with surface charge-switchable and self-amplification drug release for combating multidrug resistance cancer. Drug Deliv. 2021; 28(1):680-691. PMC: 8023596. DOI: 10.1080/10717544.2021.1905750. View

Ma Y, Chen L, Deng L, Li X, Zhao X, Jiang D . Redox-responsive self-assembled podophyllotoxin twin drug nanoparticles for enhanced intracellular drug delivery. Biomed Mater. 2023; 18(4). DOI: 10.1088/1748-605X/acd6ca. View

Ha W, Zhao X, Zhao W, Tang J, Shi Y . A colon-targeted podophyllotoxin nanoprodrug: synthesis, characterization, and supramolecular hydrogel formation for the drug combination. J Mater Chem B. 2021; 9(14):3200-3209. DOI: 10.1039/d0tb02719g. View

Gordaliza M, Castro M, DEL CORRAL J, Feliciano A . Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000; 6(18):1811-39. DOI: 10.2174/1381612003398582. View

Gordaliza M, Garcia P, del Corral J, Castro M, Gomez-Zurita M . Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives. Toxicon. 2004; 44(4):441-59. DOI: 10.1016/j.toxicon.2004.05.008. View

Shi R, Fan H, Yu X, Tang Y, Jiang J, Liang X . Advances of podophyllotoxin and its derivatives: Patterns and mechanisms. Biochem Pharmacol. 2022; 200:115039. DOI: 10.1016/j.bcp.2022.115039. View

Motyka S, Jafernik K, Ekiert H, Sharifi-Rad J, Calina D, Al-Omari B . Podophyllotoxin and its derivatives: Potential anticancer agents of natural origin in cancer chemotherapy. Biomed Pharmacother. 2022; 158:114145. DOI: 10.1016/j.biopha.2022.114145. View

Min H, Lee H . Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022; 54(10):1670-1694. PMC: 9636149. DOI: 10.1038/s12276-022-00864-3. View

10.

Baldwin E, Osheroff N . Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents. 2005; 5(4):363-72. DOI: 10.2174/1568011054222364. View

11.

Antoniou A, Nordio G, Di Paolo M, Colombo E, Gaffuri B, Polito L . 2-Hydroxyoleic Acid as a Self-Assembly Inducer for Anti-Cancer Drug-Centered Nanoparticles. Pharmaceuticals (Basel). 2023; 16(5). PMC: 10220756. DOI: 10.3390/ph16050722. View

12.

Irby D, Du C, Li F . Lipid-Drug Conjugate for Enhancing Drug Delivery. Mol Pharm. 2017; 14(5):1325-1338. PMC: 5477224. DOI: 10.1021/acs.molpharmaceut.6b01027. View

13.

Lee Y, Tan Y, Oon C . Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018; 834:188-196. DOI: 10.1016/j.ejphar.2018.07.034. View

14.

Hoelder S, Clarke P, Workman P . Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol. 2012; 6(2):155-76. PMC: 3476506. DOI: 10.1016/j.molonc.2012.02.004. View

15.

Dadwal A, Baldi A, Narang R . Nanoparticles as carriers for drug delivery in cancer. Artif Cells Nanomed Biotechnol. 2018; 46(sup2):295-305. DOI: 10.1080/21691401.2018.1457039. View

16.

Wan X, Min Y, Bludau H, Keith A, Sheiko S, Jordan R . Drug Combination Synergy in Worm-like Polymeric Micelles Improves Treatment Outcome for Small Cell and Non-Small Cell Lung Cancer. ACS Nano. 2018; 12(3):2426-2439. PMC: 5960350. DOI: 10.1021/acsnano.7b07878. View

17.

Wang R, Xuan Y, Zhao Y, Wang W, Ma P, Ju B . Cationic Nanoparticulate System for Codelivery of MicroRNA-424 and Podophyllotoxin as a Multimodal Anticancer Therapy. Mol Pharm. 2022; 19(7):2092-2104. DOI: 10.1021/acs.molpharmaceut.1c00962. View

18.

Shafei A, El-Bakly W, Sobhy A, Wagdy O, Reda A, Aboelenin O . A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomed Pharmacother. 2017; 95:1209-1218. DOI: 10.1016/j.biopha.2017.09.059. View

19.

Newman D, Cragg G . Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J Nat Prod. 2020; 83(3):770-803. DOI: 10.1021/acs.jnatprod.9b01285. View

20.

Van Maanen J, Retel J, de Vries J, Pinedo H . Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst. 1988; 80(19):1526-33. DOI: 10.1093/jnci/80.19.1526. View